Product Description
NIDO-361 is a novel small molecule that binds to the BF3 site – a distinct site from where typical AR targeting small molecules bind – to restore healthy cell function. (Sourced from: https://nidobio.com/)
Mechanisms of Action: AR Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Muscular Atrophy, Spinal *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Nido Biosciences, Inc.
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, Italy, South Korea, United Kingdom
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bulbo-Spinal Atrophy, X-Linked|Kennedy’s Disease|Muscular Atrophy, Spinal
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-507128-22-00 |
NIDO-361-002 | P2 |
Recruiting |
Kennedy’s Disease|Muscular Atrophy, Spinal |
2026-07-31 |
2025-05-02 |
Treatments |
|
NCT06411912 |
PIONEER KD | P2 |
Completed |
Bulbo-Spinal Atrophy, X-Linked|Muscular Atrophy, Spinal|Kennedy’s Disease |
2025-10-22 |
2025-10-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |